Status:
COMPLETED
Prediction of the Risk of Biochemical Relapse After Radical Prostatectomy for Prostate Cancer Using Radomics on Pre-therapeutic MRI
Lead Sponsor:
University Hospital, Brest
Conditions:
Prostatic Adenocarcinoma
Eligibility:
MALE
18+ years
Brief Summary
With 50% of post-operative biochemical failure, efficient predictive models are needed to guide post-operative management. Radiomic features are quantitative features extracted from medical imaging, ...
Eligibility Criteria
Inclusion
- Age \> 18yo
- Patients underwent radical prostatectomy
- High-risk prostate cancers: at least 1 criteria (pt3a/pT3b/pT4, R1, Gleason score \> 7)
Exclusion
- No available pre-operative MRI
- No analyzable pre-operative MRI
- proof of lymph-node involvement (cN1/2 or pN1/2)
- post-operative PSA \> 0.04ng/mL
Key Trial Info
Start Date :
June 26 2018
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 28 2018
Estimated Enrollment :
195 Patients enrolled
Trial Details
Trial ID
NCT04063800
Start Date
June 26 2018
End Date
August 28 2018
Last Update
September 12 2019
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, Brittany Region, France, 29609
2
Centre Hospitalier de Cornouaille
Quimper, Brittany Region, France, 29000